Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 133rd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Financials
Market Cap
ROE
ROA
ROCE
ROIC
D/E
Current Ratio
Gross Margin
Profit Margin
Operating Margin
XNCR
XENCOR INC
$1.18B-20.40%-14.50%-12.25%-9.80%0.396.00100.00%-87.10%-63.85%
LXEO
LEXEO THERAPEUTICS INC
$713.09M-90.50%-70.90%-82.85%-112.40%0.197.40N/AN/AN/A
BBIO
BRIDGEBIO PHARMA INC
$14.48BN/A-82.20%-86.24%-30.80%-1.513.8895.80%-225.30%-190.53%
CGEN
COMPUGEN LTD
$143.11M-53.60%-25.40%-35.53%-123.40%1.234.387.40%-400.10%-399.26%
PHAT
PHATHOM PHARMACEUTICALS INC
$1.04BN/A-94.40%-138.80%-37.00%-1.572.2387.20%-186.50%-138.77%
TECH
BIO-TECHNE CORP
$9.12B3.90%3.00%4.82%8.70%0.294.2265.40%6.40%9.43%
NVO
NOVO NORDISK A S
$222.97B67.00%21.30%47.46%56.40%2.020.7882.00%32.90%41.80%
IONS
IONIS PHARMACEUTICALS INC
$13.09B-44.30%-8.70%-7.89%-4.80%3.912.7998.80%-26.50%-17.37%
CYPH
CYPHERPUNK TECHNOLOGIES INC
$81.58M-316.10%-176.10%-1,881.63%435.00%3.231.21N/AN/AN/A
UPB
UPSTREAM BIO INC
$1.47B-28.80%-28.10%-32.23%-40.80%0.0332.67100.00%-4,386.40%-4,366.77%
SLGL
SOL-GEL TECHNOLOGIES LTD
$108.67MN/AN/AN/AN/A0.335.15N/AN/AN/A
GLTO
GALECTO INC
$42.47M-130.70%-111.30%-195.32%-1,211.70%0.343.73N/AN/AN/A
ALDX
ALDEYRA THERAPEUTICS INC
$273.14M-72.20%-47.90%-83.73%-130.90%0.582.72N/AN/AN/A
RAPT
RAPT THERAPEUTICS INC
$1.02B-61.80%-54.70%-69.33%-107.60%0.0912.04N/AN/AN/A
MDGL
MADRIGAL PHARMACEUTICALS INC
$12.98B-41.50%-26.20%-27.97%-32.00%1.183.4495.30%-39.00%-36.67%
INSM
INSMED INC
$42.02B-183.60%-54.60%-56.31%-53.90%1.504.6376.50%-264.80%-244.81%
INBX
INHIBRX BIOSCIENCES INC
$1.16B-186.10%-76.30%-103.24%-213.90%3.824.49100.00%-11,077.60%-10,433.79%
LEGN
LEGEND BIOTECH CORP
$4.12B-23.40%-14.30%-15.74%-27.80%0.692.8760.60%-26.40%-22.16%
UNCY
UNICYCIVE THERAPEUTICS INC
$133.89M-184.40%-95.50%-89.14%368.10%0.353.83N/AN/AN/A
TTRX
TURN THERAPEUTICS INC
$100.41MN/AN/AN/AN/A7.531.43N/AN/AN/A
IVVD
INVIVYD INC
$540.84M-93.00%-51.90%-63.24%-758.30%0.502.4793.30%-119.60%-119.63%
LBRX
LB PHARMACEUTICALS INC
$483.85MN/AN/AN/AN/A0.0347.60N/AN/AN/A
CNTA
CENTESSA PHARMACEUTICALS PLC
$3.56B-67.70%-47.50%-54.43%-51.00%0.4910.57100.00%-1,618.00%-1,521.18%
PEPG
PEPGEN INC
$389.11M-84.10%-65.60%-53.08%-125.70%0.1713.15N/AN/AN/A
NUVB
NUVATION BIO INC
$2.89B-55.00%-38.10%-39.44%-42.00%0.858.4854.30%-813.10%-786.53%
MLYS
MINERALYS THERAPEUTICS INC
$2.92B-48.20%-45.80%-29.73%-83.20%0.0425.50N/AN/AN/A
URGN
UROGEN PHARMA LTD
$1.02BN/A-71.00%-102.36%-74.20%-2.603.9988.00%-170.60%-151.45%
ACOG
ALPHA COGNITION INC
$115.45M-52.60%-40.80%-50.11%-1,606.00%0.376.6973.10%-262.20%-266.30%
ZBIO
ZENAS BIOPHARMA INC
$2.18B-73.50%-57.60%-70.35%-174.50%0.645.66100.00%-1,266.00%-1,264.37%
PLX
PROTALIX BIOTHERAPEUTICS INC
$143.95M11.30%7.00%12.37%18.00%0.563.0357.50%8.70%12.06%
COYA
COYA THERAPEUTICS INC
$129.31M-57.40%-49.70%-67.50%-49,060.60%0.178.73100.00%-462.30%-480.32%
NXTC
NEXTCURE INC
$29.85M-132.90%-98.60%-202.71%-149.10%0.682.97N/AN/AN/A
CGTX
COGNITION THERAPEUTICS INC
$149.18M-150.10%-95.90%-76.14%728.50%0.196.45N/AN/AN/A
DAWN
DAY ONE BIOPHARMACEUTICALS INC
$858.37M-32.10%-28.20%-31.77%-35.90%0.148.6889.40%-113.50%-108.69%
CRVS
CORVUS PHARMACEUTICALS INC
$625.09M-25.80%-20.20%-20.82%-28.70%0.128.29N/AN/AN/A
ADMA
ADMA BIOLOGICS INC
$4.71B54.00%39.40%32.05%35.70%0.327.1354.70%42.90%33.60%
HRTX
HERON THERAPEUTICS INC
$251.21MN/A-5.70%-6.97%-4.50%15.732.5673.90%-8.80%-7.15%
DARE
DARE BIOSCIENCE INC
$35.29MN/A-82.70%-183.21%165.90%9.761.18-44.70%30,568.80%30,568.80%
PLRZ
POLYRIZON LTD
$12.36M-12.40%-11.70%-18.72%-3,440.00%0.0244.04N/AN/AN/A
TCRX
TSCAN THERAPEUTICS INC
$57.32M-73.90%-45.10%-59.97%-67.10%0.826.44100.00%-1,693.00%-1,659.11%
PVLA
PALVELLA THERAPEUTICS INC
$1.17B-68.50%-45.50%-49.43%433.60%0.736.49100.00%66,162.30%52,807.55%
FGEN
FIBROGEN INC
$33.90M-126.40%124.20%213.12%161.40%-7.023.7182.70%-182.60%-182.34%
ABUS
ARBUTUS BIOPHARMA CORP
$905.85M-50.20%-37.60%-45.57%-57.70%0.2618.80100.00%-289.40%-288.70%
SEER
SEER INC
$98.19M-26.50%-23.60%-26.94%-26.10%0.1414.2550.70%-484.50%-482.85%
KURA
KURA ONCOLOGY INC
$889.32M-65.40%-30.60%-40.35%-41.40%1.685.12100.00%-208.50%-204.82%
ROIV
ROIVANT SCIENCES LTD
$15.37B-8.00%-7.00%-6.87%-9.70%0.0633.7196.40%-1,839.60%-1,665.46%
PBM
PSYENCE BIOMEDICAL LTD
$2.96MN/AN/AN/AN/A0.088.09N/AN/AN/A
XLO
XILIO THERAPEUTICS INC
$35.75M-857.90%-52.90%-75.67%265.00%-17.522.20100.00%-183.90%-183.90%
PSTV
PLUS THERAPEUTICS INC
$94.00MN/A-172.50%-334.59%276.00%2.691.29100.00%-391.30%-321.61%
ANIX
ANIXA BIOSCIENCES INC
$117.84M-63.10%-59.20%-71.32%-71.90%0.148.45N/AN/AN/A
ACIU
AC IMMUNE SA
$317.82M-83.50%-35.80%-97.78%-248.70%1.751.16100.00%-1,643.90%-1,639.75%
QTTB
Q32 BIO INC
$36.42MN/A-57.00%-90.15%-269.00%-4.134.57N/AN/AN/A
ALLR
ALLARITY THERAPEUTICS INC
$18.03M-112.00%-64.90%-125.80%277.30%0.732.33N/AN/AN/A
COEP
COEPTIS THERAPEUTICS HOLDINGS INC
$80.80M-172.70%-92.60%-95.84%-192.70%0.322.2173.00%-2,251.50%-2,195.46%
ZNTL
ZENTALIS PHARMACEUTICALS INC
$101.15M-51.50%-40.00%-51.54%-45.80%0.297.76100.00%368.10%368.64%
DBVT
DBV TECHNOLOGIES SA
$621.32M-295.60%-135.20%-204.90%-4,670.60%1.091.80100.00%-2,273.90%-2,271.65%
ERAS
ERASCA INC
$1.02B-33.10%-27.80%-32.60%-31.00%0.2110.45N/AN/AN/A
VTYX
VENTYX BIOSCIENCES INC
$584.43M-48.10%-43.90%-53.25%-50.70%0.1117.86N/AN/AN/A
IBRX
IMMUNITYBIO INC
$2.32BN/A-86.70%-48.87%-21.30%-1.995.7799.60%-422.30%-273.40%
MGX
METAGENOMI INC
$61.95M-43.20%-31.10%-41.23%-34.60%0.396.42100.00%-287.10%-291.26%
SLS
SELLAS LIFE SCIENCES GROUP INC
$289.16M-95.20%-75.10%-56.85%1,520.90%0.138.28N/AN/AN/A
ACTU
ACTUATE THERAPEUTICS INC
$174.79M-2,924.50%-250.70%-212.50%311.00%0.622.74N/AN/AN/A
CVAC
CUREVAC NV
$1.14B18.40%15.30%18.22%52.50%0.313.7093.00%182.10%232.41%
NCNA
NUCANA PLC
$0.00-253.40%-147.00%-61.57%750.70%0.254.76N/AN/AN/A
GALT
GALECTIN THERAPEUTICS INC
$402.95MN/A-269.90%24.43%-70.60%-1.090.09N/AN/AN/A
PRTA
PROTHENA CORP PUBLIC LTD CO
$557.68M-72.70%-62.50%-79.27%-3,639.10%0.206.61100.00%-2,379.60%-2,025.72%
ALGS
ALIGOS THERAPEUTICS INC
$81.81M-132.40%-74.30%-84.18%-123.30%0.534.70100.00%-3,267.60%-2,792.71%
KZR
KEZAR LIFE SCIENCES INC
$45.70M-62.50%-51.80%-71.92%-77.80%0.187.07N/AN/AN/A
RANI
RANI THERAPEUTICS HOLDINGS INC
$162.83MN/A-129.00%273.69%-132.60%-2.810.26100.00%-2,359.60%-2,053.83%
OCGN
OCUGEN INC
$424.76M-491.20%-99.20%-163.12%-157.50%15.301.85100.00%-1,192.20%-1,131.02%
TNYA
TENAYA THERAPEUTICS INC
$141.53M-95.50%-76.80%-102.71%-122.30%0.274.64N/AN/AN/A
SYRE
SPYRE THERAPEUTICS INC
$2.61B-31.20%-26.80%-32.51%-35.40%0.1110.91N/AN/AN/A
VTGN
VISTAGEN THERAPEUTICS INC
$167.86M-90.70%-76.20%-92.50%-747.70%0.225.79100.00%-8,631.90%-8,631.90%
TRVI
TREVI THERAPEUTICS INC
$1.64B-31.20%-29.30%-24.11%-50.10%0.0521.93N/AN/AN/A
PASG
PASSAGE BIO INC
$31.14M-102.10%-53.00%-87.19%-120.00%1.382.51N/AN/AN/A
EQ
EQUILLIUM INC
$77.94M-148.80%-109.40%-76.58%1,073.10%0.1210.85100.00%-555.90%-547.72%
ALT
ALTIMMUNE INC
$549.42M-54.80%-47.60%-40.73%-92.80%0.1817.18100.00%-559,433.30%-558,900.00%
GERN
GERON CORP
$868.16M-30.30%-14.00%-9.57%-6.90%1.285.9697.70%-43.60%-25.04%
RGNX
REGENXBIO INC
$702.14M-78.30%-34.50%-33.89%-26.00%2.252.6787.20%-110.30%-84.16%
CAMP
CAMP4 THERAPEUTICS CORP
$304.26M-100.10%-76.60%-68.03%-490.20%0.479.83100.00%-1,404.50%-1,404.47%
ZLAB
ZAI LAB LTD
$1.97B-25.80%-17.70%-25.28%-96.60%0.532.8761.30%-46.80%-45.75%
TNXP
TONIX PHARMACEUTICALS HOLDING CORP
$227.05M-55.20%-49.90%-42.88%-210.80%0.099.8934.30%-963.40%-963.38%
CMPX
COMPASS THERAPEUTICS INC
$917.77M-48.90%-42.50%-30.07%-58.90%0.1017.82N/AN/AN/A
NAMS
NEWAMSTERDAM PHARMA CO NV
$4.22B-29.10%-26.90%-30.36%-211.70%0.0812.57100.00%-627.30%-627.28%
CRBU
CARIBOU BIOSCIENCES INC
$167.31M-80.80%-62.70%-94.14%-69.20%0.385.54100.00%-1,690.40%-1,690.54%
EDIT
EDITAS MEDICINE INC
$246.98M-348.50%-78.60%-143.62%-160.90%14.002.86100.00%-430.80%-433.42%
IBIO
IBIO INC
$43.63M-83.60%-62.80%-34.28%-171.80%0.158.40100.00%-4,021.60%-3,983.40%
JBIO
JADE BIOSCIENCES INC
$689.14M-49.00%-44.70%-36.20%-139.20%0.139.01N/AN/AN/A
GRDX
GRIDAI TECHNOLOGIES CORP
$9.88M-888.30%-16.40%-4.86%-9.10%2.032.62N/AN/AN/A
ADCT
ADC THERAPEUTICS SA
$524.00MN/A-55.40%-50.64%-97.80%-2.224.6392.70%-222.00%-153.31%
ANRO
ALTO NEUROSCIENCE INC
$470.03M-47.40%-38.10%-43.51%-245.30%0.3215.42N/AN/AN/A
FULC
FULCRUM THERAPEUTICS INC
$703.54M-32.20%-30.00%-34.99%-38.20%0.0817.70N/AN/AN/A
SVRA
SAVARA INC
$1.41B-86.60%-65.40%-93.14%-66.40%0.497.65N/AN/AN/A
VYGR
VOYAGER THERAPEUTICS INC
$244.08M-48.90%-37.40%-49.86%-45.70%0.316.19100.00%-404.80%-402.55%
LITS
LITE STRATEGY INC
$62.90M-27.10%-26.20%-10.31%-47.00%0.0112.39N/AN/AN/A
MREO
MEREO BIOPHARMA GROUP PLC
$345.32M-75.00%-63.70%-90.19%3,290.60%0.158.7173.60%-8,314.60%-8,583.60%
FATE
FATE THERAPEUTICS INC
$132.66M-56.60%-40.20%-49.47%-40.10%0.477.87100.00%-2,187.10%-2,187.11%
OCS
OCULIS HOLDING AG
$1.16B-81.70%-61.80%-77.18%-150.90%0.294.47100.00%-36,145.10%-35,938.25%
NRXP
NRX PHARMACEUTICALS INC
$58.16MN/A-489.90%148.69%172.10%-1.580.2959.90%-15,727.70%-15,727.69%
APVO
APTEVO THERAPEUTICS INC
$19.04M-411.10%-168.00%-123.81%-519.70%0.554.03N/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Dec 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Beone Medicines (NASDAQ:ONC)


Beone Medicines (NASDAQ:ONC) is the #1 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Beone Medicines (NASDAQ:ONC) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: C, and AI: B.

Beone Medicines (NASDAQ:ONC) has a Due Diligence Score of 53, which is 30 points higher than the biotech industry average of 23.

ONC passed 18 out of 33 due diligence checks and has strong fundamentals. Beone Medicines has seen its stock return 76.99% over the past year, overperforming other biotech stocks by 122 percentage points.

Beone Medicines has an average 1 year price target of $390.88, an upside of 22.51% from Beone Medicines's current stock price of $319.06.

Beone Medicines stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Beone Medicines, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: C, Momentum: B, Sentiment: B, Safety: C, Financials: A, and AI: B.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 46, which is 23 points higher than the biotech industry average of 23.

AUPH passed 15 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 63.57% over the past year, overperforming other biotech stocks by 109 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $17.25, an upside of 8.83% from Aurinia Pharmaceuticals's current stock price of $15.85.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Aurinia Pharmaceuticals, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Innoviva (NASDAQ:INVA)


Innoviva (NASDAQ:INVA) is the #3 top biotech stock out of 617 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Innoviva (NASDAQ:INVA) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Innoviva (NASDAQ:INVA) has a Due Diligence Score of 45, which is 22 points higher than the biotech industry average of 23.

INVA passed 14 out of 33 due diligence checks and has strong fundamentals. Innoviva has seen its stock return 11.21% over the past year, overperforming other biotech stocks by 56 percentage points.

Innoviva has an average 1 year price target of $32.00, an upside of 55.11% from Innoviva's current stock price of $20.63.

Innoviva stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Innoviva, 25% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 25% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 12.13%, which is 9 percentage points higher than the biotech industry average of 2.94%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

2. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.29%, which is -1 percentage points lower than the biotech industry average of 2.94%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 49.4% indicates that its dividend yield is sustainable for the long-term.

3. Bio Techne (NASDAQ:TECH)


Bio Techne (NASDAQ:TECH) has an annual dividend yield of 0.55%, which is -2 percentage points lower than the biotech industry average of 2.94%. Bio Techne's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Bio Techne's dividend has not shown consistent growth over the last 10 years.

Bio Techne's dividend payout ratio of 64% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -0.42% in the last day, and up 0.28% over the last week. Sonnet Biotherapeutics Holdings was the among the top losers in the biotechnology industry, dropping -59.35% yesterday.

Sonnet BioTherapeutics Holdings shares are trading lower after the company announced its stockholders approved a business combination with Hyperliquid Strategies and Rorschach I.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 27.15% in the past year. It has overperformed other stocks in the biotech industry by 72 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 100.68% in the past year. It has overperformed other stocks in the biotech industry by 146 percentage points.

3. Innoviva (NASDAQ:INVA)


Innoviva (NASDAQ:INVA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Innoviva's stock has gained 11.21% in the past year. It has overperformed other stocks in the biotech industry by 56 percentage points.

Are biotech stocks a good buy now?

59.96% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 47.99% over the next year.

3.31% of biotech stocks have a Zen Rating of A (Strong Buy), 6.42% of biotech stocks are rated B (Buy), 44.93% are rated C (Hold), 32.3% are rated D (Sell), and 13.04% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 155.66x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.